06185.HK
CanSino Biologics Inc.
HKSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
HKD 29.22
−0.61%Year over year
Reported trailing growth
- Revenue
- +32.6%
- EBITDA
- +257.7%
- EBIT
- +65.8%
- EPS
- +123.8%
- Free cash flow
- +52.6%
- Operating cash flow
- -30.9%
Forward estimates
Based on analyst estimates
- Revenue
- -27.0%
- EBITDA
- +657.0%
- EPS
- +239.1%
Three-year CAGR
- Revenue
- +0.0%
- EBITDA
- +145.2%
- EBIT
- +69.9%
- Net income
- +107.2%
- EPS
- +107.2%
- Free cash flow
- +75.6%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026